By Anuradha Ramanathan
BANGALORE, Nov 9 (Reuters) - Medical diagnostics company Hologic Inc reported a fourth-quarter profit that beat market estimates by a cent, and raised its 2010 earnings forecast, but shares fell in after-market trade as some investors saw the outlook as conservative.
Shares of the company were trading widely between $14.05 and $15.35 in after-market trade.
'It is not an enthusiastic guidance but it is reasonably conservative,' Canaccord Adams analyst Matthew Scalo said.
For fiscal first-quarter ending Dec. 26, the company said it expects to earn 24 cents to 26 cents a share, excluding items, missing market expectations. It expects revenue to be between $400 million to $405 million.
Analysts were expecting Hologic to earn 30 cents a share, on revenue of $413.9 million, according to Thomson Reuters I/B/E/S.
For the fourth quarter, Hologic reported net income of $34.9 million, or 13 cents a share, compared with a loss of $144.4 million, or 56 cents a share, a year earlier. Revenue fell 9 percent to $402.8 million.
Scalo said growth in the company's breast health business in the fourth quarter was better-than-expected, even though it declined year-over-year. For the alerts, double-click
Shares of Hologic closed at $15.32 Monday on Nasdaq.
(Reporting by Anuradha Ramanathan in Bangalore; Editing by Maju Samuel) Keywords: HOLOGIC/ (anuradha.ramanathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800: Reuters Messaging: anuradha.ramanathan.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
BANGALORE, Nov 9 (Reuters) - Medical diagnostics company Hologic Inc reported a fourth-quarter profit that beat market estimates by a cent, and raised its 2010 earnings forecast, but shares fell in after-market trade as some investors saw the outlook as conservative.
Shares of the company were trading widely between $14.05 and $15.35 in after-market trade.
'It is not an enthusiastic guidance but it is reasonably conservative,' Canaccord Adams analyst Matthew Scalo said.
For fiscal first-quarter ending Dec. 26, the company said it expects to earn 24 cents to 26 cents a share, excluding items, missing market expectations. It expects revenue to be between $400 million to $405 million.
Analysts were expecting Hologic to earn 30 cents a share, on revenue of $413.9 million, according to Thomson Reuters I/B/E/S.
For the fourth quarter, Hologic reported net income of $34.9 million, or 13 cents a share, compared with a loss of $144.4 million, or 56 cents a share, a year earlier. Revenue fell 9 percent to $402.8 million.
Scalo said growth in the company's breast health business in the fourth quarter was better-than-expected, even though it declined year-over-year. For the alerts, double-click
Shares of Hologic closed at $15.32 Monday on Nasdaq.
(Reporting by Anuradha Ramanathan in Bangalore; Editing by Maju Samuel) Keywords: HOLOGIC/ (anuradha.ramanathan@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800: Reuters Messaging: anuradha.ramanathan.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2009 AFX News
